Management of patients under anticoagulants for transurethral resection of the prostate: A multicentric study by the CTMH-AFU;Prise en charge des patients sous traitement antithrombotique dans la résection transurétrale de prostate : étude multicentrique du CTMH de l'Afu

Progres en Urologie

Volumn 19, Issue 8, 2009, Pages 553-557

  Lebdai, S ^a   Robert, G ^c   Devonnec, M ^d   Fourmarier, M ^e   Haillot, O ^f   Saussine, C ^g   Azzouzi, A R ^a   De La Taille, A ^h   Descazeaud, A ^b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e IEP Aix en Provence   (France)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

Anticoagulants; BPH; Coumarin derivatives; Platelet aggregation inhibitors; Prostate; TURP

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ARTICLE; CLINICAL TRIAL; HEMATURIA; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MALE; MULTICENTER STUDY; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION;

AGED; ANTICOAGULANTS; HEMATURIA; HUMANS; LENGTH OF STAY; MALE; PATIENT READMISSION; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 68749099386     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2009.04.009     Document Type: Article

References (13)

1. Platz E.A., Smit E., Curhan G.C., Nyberg L.M., and Giovannucci E. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 59 (2002) 877-883
2. Da Silva F.C. Benign prostatic hyperplasia: natural evolution versus medical treatment. Eur Urol 32 (1997) 34-37
3. Reich O., Gratzke C., Bachmann A., Seitz M., Schlenker B., Hermanek P., et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 180 (2008) 246-249
4. Varkarakis J., Bartsch G., and Horninger W. Long-term morbidity and mortality of transurethral prostatectomy: A 10-year follow-up. The Prostate 58 (2004) 248-251
5. Prise en charge diagnostique et thérapeutique de l'hypertrophie bénigne de la prostate. Recommandations pour la pratique clinique ANAES 2003 ; www.anaes.fr.
6. Wasson J.H., Bubolz T.A., Lu-Yao G.L., Walker-Corkery E., Hammond C.S., and Barry M.J. Transurethral resection of the prostate among medicare beneficiaries: 1984 to 1997. For the patient outcomes research team for prostatic diseases. J Urol 164 (2000) 1212-1215
7. Doll H., et al. Mortality, morbidity and complications following transurethral resection of prostate for benign prostatic hypertrophy. J Urol 147 (1992) 1556-1573
8. Matani Y., Mottrie A.M., Stockle M., Voges G.E., Fichtner J., and Hohenfellner R. Transurethral prostatectomy: a long-term follow-up study of 166 patients over 80 years of age. Eur Urol 30 (1996) 414-417
9. Normand G., Guignet J., Briffaux R., Merlet B., Irani J., and Doré B. Hématurie macroscopique après resection transurétrale de prostate. Prog Urol 16 (2006) 461-463
10. Mulcahy J.J., Bradenburg R.O., Pluth J.R., and Greene L.F. Transurethral prostatic resection in patients with prosthetic cardiac valves. J Urol 113 (1975) 642-643
11. Chakravarti A., and MacDermott S. Transurethral resection of the prostate in the anticoagulated patient. Br J Urol 81 (1998) 520-522
12. Dotan Z.A., Mor Y., Leibovitch I., Varon D., Golomb J., Duvdevani M., et al. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 168 (2002) 610-613
13. Wilson R.G., Smith D., Paton G., Gollock J.M., and Bremner D.N. Prophylactic subcutaneous heparin does not increase operative blood loss in transurethral resection of the prostate. Br J Urol 62 (1988) 246-248